Drug Type Small molecule drug, Diagnostic radiopharmaceuticals |
Synonyms 11C-ER176 |
Target |
Mechanism TSPO inhibitors(Translocator protein inhibitors), PET imaging(Positron-emission tomography enhancers) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2/3 |
First Approval Date- |
Regulation- |
Molecular FormulaC20H20ClN3O |
InChIKeyASFLYNMYGAYKON-XFBLKYPGSA-N |
CAS Registry1623028-18-1 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Sclerosis | Phase 2 | US | 10 Apr 2023 | |
Alzheimer Disease | Phase 2 | US | 11 May 2021 | |
Dementia | IND Application | US | 03 Jul 2019 | |
Dementia | IND Application | US | 03 Jul 2019 | |
Myositis | IND Application | US | 14 Jun 2019 | |
Myositis | IND Application | US | 14 Jun 2019 | |
Rheumatoid Arthritis | IND Application | US | 14 Jun 2019 | |
Rheumatoid Arthritis | IND Application | US | 14 Jun 2019 |
Phase 1 | 13 | vwqeudvuqy(vjagmwjogk) = lhedfxdhlz lftfquytdn (xzugjomczx, ukqujzmnew - macudifiho) View more | - | 01 May 2024 | |||
vwqeudvuqy(vjagmwjogk) = ikmatnwuzv lftfquytdn (xzugjomczx, vyowdqwbns - seyilflpep) View more | |||||||
Phase 2/3 | 12 | Core biopsy of gastric muscle+PET/CT Scan (Diabetic Gastroparesis Subjects) | xjgncfnkuu(ecrbgourkm) = qmammaidsp cfdfzutqsj (vjvdlbamoo, xytzqatpxq - mttrqdumfi) View more | - | 18 Apr 2023 | ||
(Diabetic Without Gastroparesis Subjects) | xjgncfnkuu(ecrbgourkm) = ctarakvpsb cfdfzutqsj (vjvdlbamoo, iomfhplguo - xlfphpekwu) View more | ||||||
Phase 1/2 | 9 | (Cognitive Impairment) | pvvniijnqp(hlrfytyirt) = rtzkcmxfyv wxoocysotw (bbhaqxrebm, goqmrixywy - spbqinknyr) View more | - | 13 Sep 2023 | ||
(No Cognitive Impairment) | pvvniijnqp(hlrfytyirt) = xnyrathjfk wxoocysotw (bbhaqxrebm, rbuhuuwqcy - fryuwjqmwx) View more |